Related Experiment Video

Updated: Oct 22, 2026

A Rat Model of Ventricular Fibrillation and Resuscitation by Conventional Closed-chest Technique
09:47

A Rat Model of Ventricular Fibrillation and Resuscitation by Conventional Closed-chest Technique

Published on: April 26, 2015

The influence of a new antiarrhythmic drug, Craviten (M-71) on coronary flow

W Banaszkiewicz, A Chodera

    Polish Journal of Pharmacology and Pharmacy
    |November 1, 1980
    PubMed

    Insights

    Craviten (M-71) enhances coronary blood flow but temporarily reduces heart contraction rate and force in cats. Its short-lived effects suggest potential use for acute cardiac insufficiency with pain or arrhythmia.

    Area of Science:

    • Cardiovascular pharmacology
    • Cardiac electrophysiology

    Background:

    • Acute cardiac insufficiency presents significant clinical challenges.
    • Managing cardiac pain and arrhythmia requires effective therapeutic agents.

    Purpose of the Study:

    • To investigate the cardiovascular effects of Craviten (M-71).
    • To evaluate the potential therapeutic applications of Craviten in cardiac conditions.

    Main Methods:

    • In vitro and in situ studies on the cat heart.
    • Assessment of coronary blood flow, contraction rate, and contractile force.

    Main Results:

    • Craviten (M-71) demonstrated increased coronary flow.
    • A transient depression in the rate and contractile force of the heart was observed.
    • The drug's effects were found to be short-lasting.

    Conclusions:

    • Craviten (M-71) exhibits a unique profile of increasing coronary flow while temporarily decreasing cardiac contractility.
    • Its short duration of action suggests potential utility in managing acute cardiac insufficiency, particularly when associated with pain or arrhythmia.

    More Related Videos

    Preparation of Human Myocardial Tissue for Long-Term Cultivation10:58

    Preparation of Human Myocardial Tissue for Long-Term Cultivation

    Published on: June 2, 2022

    Real-time Evaluation of Absolute, Cytosolic, Free Ca2+ and Corresponding Contractility in Isolated, Pressurized Lymph Vessels08:46

    Real-time Evaluation of Absolute, Cytosolic, Free Ca2+ and Corresponding Contractility in Isolated, Pressurized Lymph Vessels

    Published on: March 22, 2024

    Related Concept Videos

    Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

    Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

    Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
    Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

    Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
    Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

    Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

    Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
    Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

    Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

    Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
    Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
    Heart Failure Drugs: Inotropic Agents01:26

    Heart Failure Drugs: Inotropic Agents

    Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
    Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

    Antianginal Drugs: Calcium Channel Blockers and Ranolazine

    Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
    CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...